Skip to content
Study details
Enrolling now

A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

Cybin IRL Limited
NCT IDNCT06793397ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

330

Study length

about 1.4 years

Ages

18–85

Locations

32 sites in AL, AR, AZ +14

About this study

Researchers are testing whether CYB003, an adjunctive treatment to psychological support, can help people with major depressive disorder. The trial will last for 514 days and involve approximately 330 participants.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Participate in Psychological Support
  • 2.Take CYB003
PhasePhase 3
Primary goalMontgomery-Asberg Depression Scale (MADRS)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low15%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Montgomery-Asberg Depression Scale (MADRS)

Secondary: The Beck Depression Inventory - Second Edition (BDI-II), The Generalized Anxiety Disorder 7-Item Scale (GAD-7), The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)

Body systems

Psychiatry / Mental Health